Cigna caps copays for Wegovy, Zepbound: 5 notes 

Evernorth, the Cigna Group’s health services arm, will cap out-of-pocket costs for Zepbound and Wegovy, two GLP-1 drugs, at $200. 

Members can save up to $3,600 a year compared to purchasing the drugs directly or through consumer programs, according to a May 21 news release. 

Here are five things to know: 

1. Evernorth negotiated with the medications’ manufacturers to reach the copay cap. 
   
   
2. The company will also implement easier prior authorization processes for Wegovy and Zepbound, according to the release. 
   
   
3. Health plan sponsors will see a significant decrease in the cost per prescription of the drugs, Evernorth said. 
   
   
4. Wegovy and Zepbound, GLP-1 drugs approved for weight loss, can cost upwards of $1,000 a month without insurance. 
   
   
5. Cigna has implemented several other programs designed to manage the cost of weight loss drugs. In 2024, the company launched EncircleRx, a financial model to cap the costs of GLP-1s for employers. The program has grown to 9 million members. 

At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.